Plain-English translation of NCT06990269 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new medication given by injection under the skin, can slow or stop vision loss in people with geographic atrophy—a condition where the center of the retina gradually breaks down due to age-related macular degeneration. Half of the participants will receive the medication, and half will receive a placebo (a saline injection with no active drug) to see if the treatment actually works. Researchers will measure whether this treatment helps preserve vision and study how safe it is.
Geographic atrophy is a progressive eye condition that can lead to significant vision loss and blindness, and there are currently limited treatment options available. This trial is being conducted to see if this new medication can offer hope to patients by slowing the disease's progression.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either injections or placebo injections under the skin. You'll make regular visits to the clinic for injections, eye imaging, and vision tests to track how the medication is working. The study involves about 240 participants total, and you'll need to commit to the full series of study visits and vaccinations required by the protocol.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States